2026北京两会丨对话市政协委员刘伟：从“研”到“用”，北京创新药“全链条”发力

Core Viewpoint - The "New 32 Measures" introduced by Beijing's healthcare authorities aim to significantly enhance the development of innovative pharmaceuticals by streamlining clinical trial processes, improving market access, and providing financial support, thereby creating a more conducive environment for drug innovation and manufacturing [3][4]. Group 1: Policy Measures - The "New 32 Measures" will compress the clinical trial approval timeline from 60 working days to 30 working days and reduce the review period for supplementary drug applications from 200 working days to 60 working days [4]. - The measures encourage local production of innovative drugs and promote the digital transformation of pharmaceutical manufacturing, which will help reduce long-term costs for companies [4]. - A total of 500 billion yuan will be allocated for an industry fund and 100 billion yuan for a merger fund to address the challenges of long R&D cycles and high funding requirements [4]. Group 2: Industry Advantages - Beijing is recognized for its comprehensive advantages in the pharmaceutical and healthcare sector, including a concentration of regulatory bodies, numerous research institutions, and a large pool of high-level medical talent [5]. - The city has over 90 universities and the highest number of national-level biomedical research laboratories, providing robust support for R&D activities [5]. - The local government has identified the healthcare industry as a key growth engine, with a market size exceeding one trillion yuan, and is committed to optimizing the industry layout through coordinated mechanisms [5]. Group 3: AI Integration - The integration of AI and big data into the pharmaceutical sector is accelerating the pace of medical research and drug development, transitioning from exploratory phases to practical applications that enhance decision-making and efficiency [6]. - AI is showing potential in drug development by improving target screening, molecular design, and data integration, which could significantly reduce the costs and time associated with bringing new drugs to market [6]. Group 4: Recommendations for Future Development - It is recommended to deepen collaboration among hospitals, universities, and enterprises to foster innovation in drug development, focusing on clinical needs [7]. - Strengthening financial support and policy backing is essential to attract social capital into innovative drug R&D and enhance financing services for public listings [7]. - Establishing a robust talent support system that includes a diverse range of professionals is crucial for sustaining innovation across the pharmaceutical value chain [8].